Subscriber login:
Remember me
QUALITATIVE & QUANTITATIVE PRIMARY MARKET INSIGHTS
Understand payer and prescriber perspectives on impactful new drug launches with IPD’s qualitative, quantitative, and syndicated Primary Market Insights.
With IPD’s Primary Market Insights, explore new-entrant adoption and prospective payer management with key takeaways from moderated discussions and comprehensive surveys with key opinion leaders, disease-area experts, physicians, and payers.
IPD’s two-pronged primary research approach allows for a comprehensive review of
new-entrant adoption and prospective payer management.
Qualitative Insights
Deep discussions to explore assumptions, understand motivations, and uncover catalysts for success or failure take place between respondents and IPD experts prior to potential product launch
Quantitative Insights
Expertly curated surveys with questions that further explore topics from our qualitative findings are completed by targeted respondents continuously after product launch
IPD gathers key insights to predict success in the market, answering questions like these:
Is the product endorsed by key opinion leaders?
How will payers cover the product?
Is it easy to
monitor efficacy and/or side effects?
Is the product easy to administer?
Our expertly moderated discussions and continuous surveys power IPD’s succinct coverage on new-entrant adoption and prospective payer management offered through our Primary Market Insights subscription.
Explore Recent Reports
June 2024
Evaluation and Impact of Biosimilars: Perceptions from Payer and Health-System Experts
Our recent Primary Market Insights report summarizes insights from over 110 regional and national payer and health-system experts regarding biosimilar management strategy, the financial impact of biosimilars, and interchangeability. With input from vice presidents of pharmacy, pharmacy directors, clinical pharmacists, and purchasing/operations executives, the report examines how organizations are measuring biosimilar savings, planning for preferred products, covering Humira biosimilars, and reacting to price changes on long-acting insulin glargine products, and more.
May 2024
Obesity: Evolving Perceptions from Providers and Payers on Treatments for Chronic Weight Management
IPD’s recent Primary Market Insights report, “Obesity: Evolving Perceptions from Providers and Payers on Treatments for Chronic Weight Management,” analyzes the results from surveys completed by 30 primary care physicians and 30 endocrinologists to assess their prescribing preferences among anti-obesity medications (AOMs). These surveys capture early assessments of Eli Lilly’s Zepbound (tirzepatide) and Novo Nordisk’s Wegovy (semaglutide) for reduction in the risk of major adverse cardiovascular events (MACE) as well as anticipated usage of oral semaglutide.